Photo from Rami Manochakian/X
Apr 26, 2024, 10:07
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter:
”HOT OFF THE PRESS.
BIG NEWS.
U.S. FDA approves adjuvant Alectinib following surgery in patients with stage IB-IIIA ALK+ Non-Small Cell Lung Cancer based on results of Alina trial:
High DFS HR: 0.24 (compared with adjuvant chemotherapy).”
Read further.
Source: Rami Manochakian/X